TY - JOUR
T1 - Hepatobiliary tumor organoids for personalized medicine
T2 - a multicenter view on establishment, limitations, and future directions
AU - van Tienderen, Gilles S.
AU - Li, Ling
AU - Broutier, Laura
AU - Saito, Yoshimasa
AU - Inacio, Patricia
AU - Huch, Meritxell
AU - Selaru, Florin M.
AU - van der Laan, Luc J.W.
AU - Verstegen, Monique M.A.
N1 - Funding Information:
We thank Prof. Kourosh Saeb-Parsy (Addenbrokes Hospital, University of Cambridge), Prof. Jan IJzermans, dr. Bas Groot Koerkamp, dr. Jeroen de Jonge (surgeons Erasmus MC University Medical Center Rotterdam), and Prof. Yae Kanai (Department of Pathology, Keio University School of Medicine, Tokyo, Japan) for providing patient material. We thank Mr. Robert Arnes-Benito and Ms. Kübra Köten for characterization of tumor organoid samples. M.H. is recipient of a Lise Meitner Excellence Program Award from the Max Planck Society. F.M.S. received financial support through a grant from the NIH ( EB017742 ). G.S.v.T. is funded by the Erasmus MC Human Disease Model Award 2018 ( HDMA-380801 ). The lab of L.J.W.v.d.L. received financial support from Netherlands Organization for Health Research and Development (ZonMw) InnoSysTox grant (project number 114027003), the Dutch Digestive Foundation (MLDS-Diagnostics project number D16-26), and the Dutch Cancer Society (project number 10496). We thank N. Delleman for her help in creating the schematic figure with BioRender.com . For the Keio center, this study was approved by the Ethics Committees of the National Cancer Center (Tokyo, Japan) and Keio University. For Johns Hopkins Hospital, tissue was obtained under an IRB-approved informed consent. For Erasmus MC, use of tissue was approved by the Medical Ethical Council of the Erasmus MC. For the Cambridge center, all specimens were obtained from Cambridge University Hospitals NHS Trust—Approval by NRES Committee London—Westminster or from the Erasmus MC. Written informed consent was obtained from all patients.
Funding Information:
We thank Prof. Kourosh Saeb-Parsy (Addenbrokes Hospital, University of Cambridge), Prof. Jan IJzermans, dr. Bas Groot Koerkamp, dr. Jeroen de Jonge (surgeons Erasmus MC University Medical Center Rotterdam), and Prof. Yae Kanai (Department of Pathology, Keio University School of Medicine, Tokyo, Japan) for providing patient material. We thank Mr. Robert Arnes-Benito and Ms. K?bra K?ten for characterization of tumor organoid samples. M.H. is recipient of a Lise Meitner Excellence Program Award from the Max Planck Society. F.M.S. received financial support through a grant from the NIH (EB017742). G.S.v.T. is funded by the Erasmus MC Human Disease Model Award 2018 (HDMA-380801). The lab of L.J.W.v.d.L. received financial support from Netherlands Organization for Health Research and Development (ZonMw) InnoSysTox grant (project number 114027003), the Dutch Digestive Foundation (MLDS-Diagnostics project number D16-26), and the Dutch Cancer Society (project number 10496). We thank N. Delleman for her help in creating the schematic figure with BioRender.com. For the Keio center, this study was approved by the Ethics Committees of the National Cancer Center (Tokyo, Japan) and Keio University. For Johns Hopkins Hospital, tissue was obtained under an IRB-approved informed consent. For Erasmus MC, use of tissue was approved by the Medical Ethical Council of the Erasmus MC. For the Cambridge center, all specimens were obtained from Cambridge University Hospitals NHS Trust?Approval by NRES Committee London?Westminster or from the Erasmus MC. Written informed consent was obtained from all patients. M.H. is an inventor in a patent on liver organoids. F.M.S. is an inventor in a patent for liver cancer treatment (PCT/US2021/016849, 17/623,060, 16/479,652). The other authors declare no conflict of interest.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/3/14
Y1 - 2022/3/14
N2 - Reliable establishment of tumor organoids is paramount to advance applications of organoid technology for personalized medicine. Here, we share our multi-center experience on initiation and tumorigenic confirmation of hepatobiliary cancer organoids. We discuss current concerns, propose potential solutions, and provide future perspectives for improvements in hepatobiliary cancer organoid establishment.
AB - Reliable establishment of tumor organoids is paramount to advance applications of organoid technology for personalized medicine. Here, we share our multi-center experience on initiation and tumorigenic confirmation of hepatobiliary cancer organoids. We discuss current concerns, propose potential solutions, and provide future perspectives for improvements in hepatobiliary cancer organoid establishment.
UR - http://www.scopus.com/inward/record.url?scp=85125895436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125895436&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2022.02.001
DO - 10.1016/j.ccell.2022.02.001
M3 - Comment/debate
C2 - 35148815
AN - SCOPUS:85125895436
SN - 1535-6108
VL - 40
SP - 226
EP - 230
JO - Cancer Cell
JF - Cancer Cell
IS - 3
ER -
